Home/Pipeline/BP1001-A

BP1001-A

Advanced Solid Tumors

Phase 1Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active

Company

Bio-Path Holdings

About Bio-Path Holdings

Bio-Path Holdings is an oncology-focused biotech developing non-toxic, targeted cancer therapies for fragile patients ineligible for standard chemotherapy. Its core innovation is the DNAbilize® liposomal delivery platform, designed to concentrate antisense drugs at the tumor site while sparing healthy tissue. The company's strategy centers on advancing its lead asset, prexigebersen, in AML while exploring its platform's utility in solid tumors and other blood cancers through earlier-stage candidates. Recent leadership changes aim to revitalize clinical progress and corporate strategy.

View full company profile

Therapeutic Areas

Oncology Hematologic Cancer Solid Tumors

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion